Bayer Healthcare is stepping up with $155 million in cash and a big near-term milestone in exchange for the development and commercialization rights to an experimental anticoagulant from Isis Pharmaceuticals.
Under investigation by the FDA following claims of dangerous side effects and fraudulent clinical trial data, Bayer has released new data from a long-term study the German drugmaker says supports the safety and effectiveness of its Essure contraceptive inserts.
The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset valuations ever upward.
Large pharma companies are posting 530% more tweets a week than in 2013, a study by Ogilvy Healthworld found. The healthcare communications group tracked the social media activity of 14 large pharma companies for one week per month over three months.
Bayer had hoped to sell a veterinary med plant in Missouri that it picked up a few years ago from Teva. But no one has come forward, so the German drugmaker will close the plant and lay off 130 people.
Fitch Ratings is raising the flag on pharma M&A. The credit ratings agency says the current spate of dealmaking is putting some pressure on European Big Pharma players.
Bayer said it will boost its already big footprint in the Bay Area with a $100 million investment in its Berkeley, CA, facility that is focused on developing new treatments for hemophilia.
German drugmaker Bayer is investing $100 million in its Berkeley, CA, R&D outpost, blueprinting a new testing facility to support its work developing new treatments for hemophilia.
Bayer is plotting a pair of Phase III trials for its lead oncology treatment, hoping to crack the crowded field of new blood cancer drugs with a targeted therapy of its own.
Marijn Dekker's time in the Bayer CEO chair is winding down, and the Dutchman has a couple of big items left on his to-do list before he turns over the reins. But thanks to his penchant for risk-taking, in the 5-plus years he's been with the German pharma, he's gotten plenty done already.